Patent Opposition Database

Hide annotations

Related patent application (please put in national patent application/publication number or PCT application/publication number): AR107548A1
Who filed: CILFA
Country: Argentina
Opposition type: Pre-Grant
Opposition status: Under Examination
Date: 16-08-2018
Patent type: Polymorphs

Click within the document, or manually enter the page number below

Médecins Sans Frontières (MSF) opposition, Velpatasvir, (CN103328480A/CN201280004097.2)

Countries: China Date: 2018
Delhi Network of Positive People (DNP+) opposition, Velpatasvir, (201627039572)

Countries: India Date: 2018
DNP+ and I-MAK opposition, Pibrentasvir, (1310/DELNP/2013)

Countries: India Date: 2018
GTPI - Grupo de Trabalho sobre Propriedade Intelectual opposition, Sofosbuvir, (PI0410846-9)

Countries: Brazil Date: 2018
GTPI - Grupo de Trabalho sobre Propriedade Intelectual opposition, Sofosbuvir, (PI0410846-9)

Countries: Brazil Date: 2018
Delhi Network of Positive People (DNP+) opposition, Sofosbuvir/Velpatasvir, (201627008488)

Countries: India Date: 2018
CILFA opposition, Desmopressin, (AR107948A2)

Countries: Argentina Date: 2018
CILFA opposition, eltrombopag, (AR107711A2)

Countries: Argentina Date: 2018
CILFA opposition, progesterone, (AR108074A1)

Countries: Argentina Date: 2018
CILFA opposition, Firsocostat - 2-(R)-2-(I-(2-(2-methoxyphenyl)-2- tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol2-yl)-2,4-dioxo-1,2-dihydrothieno[2, 3-d]pyrlmidin-3 (4H)- yl)-2-methylpropanoic acid, (AR107790A1)

Countries: Argentina Date: 2018

Cilfa Opposition, Tlr7 Agonists (Jnj 4964), (Ar107548 A1)